BR112013033448A2 - células deficientes em ácido cmp-n-acetilneuramínico hidroxilase e/ou glicoproteína alfa-1,3-galactosiltransferase - Google Patents

células deficientes em ácido cmp-n-acetilneuramínico hidroxilase e/ou glicoproteína alfa-1,3-galactosiltransferase

Info

Publication number
BR112013033448A2
BR112013033448A2 BR112013033448A BR112013033448A BR112013033448A2 BR 112013033448 A2 BR112013033448 A2 BR 112013033448A2 BR 112013033448 A BR112013033448 A BR 112013033448A BR 112013033448 A BR112013033448 A BR 112013033448A BR 112013033448 A2 BR112013033448 A2 BR 112013033448A2
Authority
BR
Brazil
Prior art keywords
cmp
acetylneuraminic acid
galactosyltransferase
glycoprotein alpha
deficient cells
Prior art date
Application number
BR112013033448A
Other languages
English (en)
Other versions
BR112013033448B1 (pt
Inventor
J George Henry
Mascarenhas Joaquina
Achtien Katherine
J Kayser Kevin
Lin Nan
N Collingwood Trevor
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Publication of BR112013033448A2 publication Critical patent/BR112013033448A2/pt
Publication of BR112013033448B1 publication Critical patent/BR112013033448B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18002—CMP-N-acetylneuraminate monooxygenase (1.14.18.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Abstract

resumo patente de invenção: "células deficientes em ácido cmp-n-acetilneuramínico hidroxilase e/ou glicoproteína alfa-1,3-galactosiltransferase". a presente invenção fornece linhagens celulares de mamífero não humano que são deficientes em cmp-neu5ac hidroxilase (cmah) e/ou glicoproteína alfa-1,3-galactosiltransferase (ggta1). também são fornecidos métodos para utilizar as células aqui reveladas para produzir proteínas recombinantes com padrões de glicosilação semelhantes aos humanos. 20116591v1
BR112013033448-7A 2011-06-30 2012-06-29 Método para produzir uma proteína recombinante com um padrão de glicosilação semelhante ao de humano BR112013033448B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503436P 2011-06-30 2011-06-30
US61/503,436 2011-06-30
PCT/US2012/045027 WO2013003767A2 (en) 2011-06-30 2012-06-29 Cells deficient in cmp-n-acetylneuraminic acid hydroxylase and/or glycoprotein alpha-1,3-galactosyltransferase

Publications (2)

Publication Number Publication Date
BR112013033448A2 true BR112013033448A2 (pt) 2017-01-31
BR112013033448B1 BR112013033448B1 (pt) 2022-01-25

Family

ID=47391045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033448-7A BR112013033448B1 (pt) 2011-06-30 2012-06-29 Método para produzir uma proteína recombinante com um padrão de glicosilação semelhante ao de humano

Country Status (8)

Country Link
US (2) US8980583B2 (pt)
EP (1) EP2726604B1 (pt)
JP (1) JP2014520533A (pt)
KR (1) KR20140045398A (pt)
CN (1) CN103781900A (pt)
BR (1) BR112013033448B1 (pt)
ES (1) ES2671733T3 (pt)
WO (1) WO2013003767A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2671733T3 (es) 2011-06-30 2018-06-08 Sigma Aldrich Co. Llc Células deficientes en ácido CMP-N-acetilneuramínico hidroxilasa y/o glucoproteína alfa-1,3-galactosil transferasa
US20140115728A1 (en) 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
EA201591229A1 (ru) * 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
CA2909139C (en) * 2013-04-18 2021-07-06 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity
CN106062196B (zh) * 2013-04-30 2020-01-21 建国大学校产业学校协力团 Cmp-乙酰神经氨酸羟化酶打靶载体、载体转导的异种移植用转基因动物及其制造方法
US11060083B2 (en) 2013-07-19 2021-07-13 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
CN105392885B (zh) 2013-07-19 2020-11-03 赖瑞克斯生物科技公司 用于产生双等位基因敲除的方法和组合物
CN104341503A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗cd20的人抗体
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
EA201691696A1 (ru) 2014-04-25 2017-03-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
EP3207055A1 (en) * 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
US10858671B2 (en) 2014-12-12 2020-12-08 University Of Copenhagen N-glycosylation
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
KR20210039553A (ko) 2019-10-02 2021-04-12 주식회사 디맥스 치과용 지르코니아 소재의 표면 처리방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE45795E1 (en) 1994-08-20 2015-11-10 Gendaq, Ltd. Binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
AU746454B2 (en) 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
EP1465481A4 (en) * 2001-12-21 2007-09-12 Univ Missouri KNOCK-OUT PORK AND METHODS OF MAKING THE SAME
WO2003064658A1 (en) 2002-02-01 2003-08-07 Arbor Vita Associates, Inc. Alpha 1,3 galactosyltransferase mutant pigs
CA2507486A1 (en) * 2002-08-14 2004-02-26 Immerge Biotherapeutics, Inc. .alpha.(1,3)-galactosyltransferase null cells, methods of selecting and .alpha.(1,3)-galactosyltransferase null swine produced therefrom
WO2004028243A2 (en) * 2002-08-21 2004-04-08 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ITMI20031909A1 (it) 2003-10-03 2005-04-04 Keryos Spa Linee cellulari di mammifero modificate per la produzione di glicoproteine ricombinanti.
JP2007529278A (ja) * 2004-03-17 2007-10-25 レビビコア， インコーポレイテッド 機能的α１，３ガラクトシルトランスフェラーゼを欠く動物に由来する組織生成物
US8232448B2 (en) 2005-06-08 2012-07-31 The Regents Of The University Of California Transgenic mouse with a homozygous mutation in the CMAH gene
KR101419729B1 (ko) 2005-07-26 2014-07-17 상가모 바이오사이언스 인코포레이티드 외래 핵산 서열의 표적화된 통합 및 발현
WO2008063982A2 (en) 2006-11-13 2008-05-29 Procell Corp High mannose glycoprotein epitopes
US20100145032A1 (en) 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US20110030072A1 (en) 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
AU2009338190C1 (en) 2009-01-22 2014-07-17 Momenta Pharmaceuticals, Inc. Galactose-alpha-1, 3-galactose-containing N-glycans in glycoprotein products derived from CHO cells
RU2012122557A (ru) 2009-11-11 2013-12-20 Момента Фармасьютикалз, Инк. Гликозил-трансфераза китайского хомячка и сопутствующие способы
ES2671733T3 (es) 2011-06-30 2018-06-08 Sigma Aldrich Co. Llc Células deficientes en ácido CMP-N-acetilneuramínico hidroxilasa y/o glucoproteína alfa-1,3-galactosil transferasa

Also Published As

Publication number Publication date
CN103781900A (zh) 2014-05-07
EP2726604B1 (en) 2018-04-04
WO2013003767A3 (en) 2014-01-23
US20150152463A1 (en) 2015-06-04
EP2726604A4 (en) 2015-08-12
US20130004992A1 (en) 2013-01-03
US8980583B2 (en) 2015-03-17
KR20140045398A (ko) 2014-04-16
BR112013033448B1 (pt) 2022-01-25
ES2671733T3 (es) 2018-06-08
EP2726604A2 (en) 2014-05-07
JP2014520533A (ja) 2014-08-25
US9062338B1 (en) 2015-06-23
WO2013003767A2 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
BR112013033448A2 (pt) células deficientes em ácido cmp-n-acetilneuramínico hidroxilase e/ou glicoproteína alfa-1,3-galactosiltransferase
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
AU2022200207B2 (en) Compositions and methods for induced tissue regeneration in mammalian species
BR112019000046A2 (pt) alfa-amilases para combinação com glucoamilases para aumentar a sacarificação
MX2016008251A (es) Medios para cultivo celular.
SG10201809901SA (en) Generating Pluripotent Cells De Novo
BR112015007319A2 (pt) composições e métodos para produzir glicoproteínas
MX367605B (es) Composiciones de nanopartículas lipídicas y métodos para administración de arnm.
BR112014026186A2 (pt) método de transfecção celular
BR112012018163A2 (pt) métodos e composições para exibição de um polipeptídeo sobre a superfície de uma célula de levredura
WO2011146843A3 (en) Thermophotovoltaic energy generation
BR112013031422A2 (pt) métodos para converter material lignocelulósico em produtos úteis
BR112014032560A2 (pt) células para produzir iduronato-2-sulfatase recombinante
BR112014019901A8 (pt) Proteínas de fator viii recombinante
BR112016007547A2 (pt) ?vetor de expressão bicistrônico para expressão de anticorpos e método para a produção de anticorpos usando o mesmo?
ES2570382T3 (es) Composiciones y métodos para la producción de azúcares fermentables
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
BR112015021189A2 (pt) métodos de banco de células de alta densidade
BR112014026206A2 (pt) sistemas e métodos celulares para melhorar a síntese de ácidos graxos através da expressão da desidrogenase
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
MY170889A (en) Car enzymes and improved production of fatty alcohols
EP2582792A4 (en) HEART OF CARDIOMYOCYTES WITH DIALYSATED SERUM
WO2014152137A8 (en) Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
BR112014032544A2 (pt) método para produzir iduronato-2-sulfatase recombinante

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: A NOTIFICACAO DE DEFERIMENTO FOI EFETUADA COM INCORRECAO NO QUADRO 1 .

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2012, OBSERVADAS AS CONDICOES LEGAIS.